Company: NGVT
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001653477-25-000015
Chunk: 1107

Company: Ingevity Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 1107
---
 the periods presented.Years Ended December 31,In millions202420232022Foreign currencyForeign currency translation adjustment (1)$0.2 $— $— Total before tax0.2 — — (Provision) benefit for income taxes— — — Amount included within net income (loss)$0.2 $— $— Derivative InstrumentsCurrency exchange contracts (2)$0.1 $(0.7)$2.0 Natural gas contracts (3)(2.5)(3.2)6.5 Interest rate swaps (5)— — 1.7 Total before tax(2.4)(3.9)10.2 (Provision) benefit for income taxes0.6 0.9 (2.4)Amount included within net income (loss)$(1.8)$(3.0)$7.8 Pension and other postretirement benefitsAmortization of prior service credit (costs) (3)$(0.1)$(0.1)$(0.1)Amortization of unrecognized net actuarial and other gains (losses) (4)— — — Recognized gain (loss) due to curtailment and settlement (3)(0.2)— (0.2)Total before tax(0.3)(0.1)(0.3)(Provision) benefit for income taxes0.1 0.1 0.1 Amount included within net income (loss)$(0.2)$— $(0.2)_______________(1) Included within "Restructuring and other (income) charges, net" on the consolidated statements of operations.(2) Included within "Net sales" on the consolidated statements of operations.(3) Included within "Cost of sales" on the consolidated statements of operations.(4) Included within "Other (income) expense, net" on the consolidated statements of operations.(5) Included within "Interest income" on the consolidated statements of operations.Share Repurchases On July 25, 2022, our Board of Directors authorized the repurchase of up to $500.0 million of our common stock (the "2022 Authorization"), and rescinded the prior outstanding repurchase authorization with respect to the shares that remained unused under the prior authorization. Shares under the 2022 Authorization may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation